PSMA-Guided Ablation of the Prostate

Launched by UNIVERSITY OF ALBERTA · Aug 14, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "PSMA-Guided Ablation of the Prostate," is investigating a new imaging method called PSMA PET to see if it can provide better accuracy in diagnosing prostate cancer compared to the standard MRI tests. The study focuses on men who have been diagnosed with localized prostate cancer and are eligible for a type of treatment called focal therapy. The main question is whether using PSMA PET can help doctors better determine the extent of the cancer, which may lead to fewer instances of leftover cancer after treatment.

To participate, men must be over 50 years old, have specific cancer characteristics, and meet certain health criteria. Eligible participants will be randomly assigned to either receive a PSMA PET scan or no additional imaging before they undergo treatment. After 12 months, all participants will undergo follow-up scans and biopsies to check for any signs of cancer recurrence. This trial is currently recruiting men who meet these criteria, and it's an important step in potentially improving prostate cancer treatment outcomes.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \> 50
• • 2. Clinical stage \< T2b
• • 3. PSA \< 15
• • 4. Combined targeted and systematic MRI-guided biopsy shows unilateral Gleason Grade Group 2 or 3 prostate cancer
• Exclusion Criteria:
• • 1. Unable to obtain consent
• • 2. Weight \>250 kg (weight limitation of scanners)
• • 3. Unable to lie flat for 30 minutes to complete the PET imaging
• • 4. Lack of intravenous access
• • 5. eGFR \< 40 mL/min/1.73 m2 and/or a history of a severe reaction to CT contrast
• • 6. Prior androgen deprivation therapy or radiation therapy to prostate gland